Profile data is unavailable for this security.
About the company
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
- Revenue in USD (TTM)0.00
- Net income in USD-24.83m
- Incorporated2017
- Employees2.00
- LocationNRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
- Phone+1 (484) 254-6134
- Fax+1 (302) 575-1642
- Websitehttps://www.nrxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Athira Pharma Inc | 0.00 | -113.45m | 16.54m | 65.00 | -- | 0.1985 | -- | -- | -2.97 | -2.97 | 0.00 | 2.17 | 0.00 | -- | -- | 0.00 | -71.06 | -30.73 | -83.81 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Galecto Inc | 0.00 | -25.43m | 16.55m | 13.00 | -- | 0.6098 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
Mira Pharmaceuticals Inc | 0.00 | -12.78m | 16.55m | 3.00 | -- | 7.46 | -- | -- | -0.8562 | -0.8562 | 0.00 | 0.1501 | 0.00 | -- | -- | 0.00 | -373.77 | -- | -737.47 | -- | -- | -- | -- | -- | -- | -3.17 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
Evaxion Biotech A/S - ADR | 278.00k | -15.21m | 16.67m | 49.00 | -- | 12.91 | -- | 59.97 | -36.98 | -36.98 | 0.1048 | 0.2316 | 0.0174 | -- | 0.3493 | 5,673.47 | -95.08 | -100.11 | -126.11 | -131.65 | -- | -- | -5,469.42 | -131,560.30 | -- | -- | 0.8933 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Cell Source Inc | 0.00 | -6.45m | 16.78m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
BioVie Inc | 0.00 | -37.18m | 16.88m | 18.00 | -- | 0.8891 | -- | -- | -9.63 | -9.63 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
Ibio Inc | 50.00k | -17.13m | 16.99m | 26.00 | -- | 0.6749 | -- | 339.77 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
Aprea Therapeutics Inc | 1.28m | -12.93m | 17.00m | 7.00 | -- | 0.665 | -- | 13.33 | -3.03 | -3.03 | 0.2898 | 4.95 | 0.0435 | -- | -- | 182,241.40 | -44.09 | -68.66 | -50.11 | -77.19 | -- | -- | -1,013.41 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
NRX Pharmaceuticals Inc | 0.00 | -24.83m | 17.52m | 2.00 | -- | -- | -- | -- | -1.62 | -1.62 | 0.00 | -1.70 | 0.00 | -- | -- | -- | -197.97 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -189.12 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
OpGen Inc | 1.96m | -22.39m | 17.55m | 100.00 | -- | -- | -- | 8.93 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
Spruce Biosciences Inc | 9.57m | -43.11m | 18.17m | 22.00 | -- | 0.3071 | -- | 1.90 | -1.05 | -1.05 | 0.2338 | 1.43 | 0.095 | -- | -- | 330,069.00 | -42.79 | -41.24 | -52.43 | -46.49 | -- | -- | -450.38 | -1,774.39 | -- | -117.26 | 0.0412 | -- | -- | -- | -3.77 | -- | -- | -- |
Biomx Inc | 0.00 | -26.25m | 18.25m | 58.00 | -- | -- | -- | -- | -0.4575 | -0.4575 | 0.00 | 0.3929 | 0.00 | -- | -- | 0.00 | -47.79 | -- | -57.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
Finch Therapeutics Group Inc | 0.00 | -14.17m | 18.31m | 18.00 | -- | 1.29 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
Lyra Therapeutics Inc | 1.82m | -101.39m | 18.46m | 87.00 | -- | 0.5959 | -- | 10.14 | -1.61 | -1.61 | 0.0294 | 0.4733 | 0.0165 | -- | -- | 20,681.82 | -92.07 | -58.01 | -108.51 | -68.69 | -- | -- | -5,570.88 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
Matinas BioPharma Holdings Inc | 0.00 | -22.91m | 18.51m | 32.00 | -- | 0.969 | -- | -- | -5.10 | -5.10 | 0.00 | 3.81 | 0.00 | -- | -- | 0.00 | -78.48 | -44.62 | -85.80 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.001 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 144.01k | 1.35% |
AdvisorShares Investments LLCas of 30 Jun 2024 | 108.09k | 1.01% |
Geode Capital Management LLCas of 30 Jun 2024 | 65.66k | 0.61% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 29.07k | 0.27% |
Virtu Americas LLCas of 30 Jun 2024 | 17.04k | 0.16% |
One Wealth Management Investment & Advisory Services LLCas of 30 Jun 2024 | 15.04k | 0.14% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 12.27k | 0.12% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 11.42k | 0.11% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 7.50k | 0.07% |
Texas Capital Bank Wealth Management Services, Inc.as of 31 Mar 2024 | 6.33k | 0.06% |